Phase I, First in Human (FIH), Randomised, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study in Healthy Volunteers with Mild to Moderate Onychomycosis.
Phase of Trial: Phase I/II
Latest Information Update: 15 Feb 2018
Price : $35 *
At a glance
- Drugs HXP-124 (Primary)
- Indications Onychomycosis
- Focus Adverse reactions; First in man
- Sponsors Hexima
- 31 Jan 2018 New trial record
- 24 Jan 2018 According to the Hexima media release, preliminary trial results are expected to be available in mid-late 2018.
- 24 Jan 2018 According to the Hexima media release, first patient has been dosed in this trial.